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Background: The risk of many cancers is higher in subjects with a family history (FH) of cancer at a concordant site.
However, few studies investigated FH of cancer at discordant sites.
Patients and methods: This study is based on a network of Italian and Swiss case–control studies on 13 cancer sites
conducted between 1991 and 2009, and including more than 12 000 cases and 11 000 controls. We collected
information on history of any cancer in ﬁrst degree relatives, and age at diagnosis. Odds ratios (ORs) for FH were
calculated by multiple logistic regression models, adjusted for major confounding factors.
Results: All sites showed an excess risk in relation to FH of cancer at the same site. Increased risks were also found for
oral and pharyngeal cancer and FH of laryngeal cancer (OR = 3.3), esophageal cancer and FH of oral and pharyngeal
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cancer (OR = 4.1), breast cancer and FH of colorectal cancer (OR = 1.5) and of hemolymphopoietic cancers (OR = 1.7),
ovarian cancer and FH of breast cancer (OR = 2.3), and prostate cancer and FH of bladder cancer (OR = 3.4). For most
cancer sites, the association with FH was stronger when the proband was affected at age <60 years.
Conclusions: Our results point to several potential cancer syndromes that appear among close relatives and may
indicate the presence of genetic factors inﬂuencing multiple cancer sites.
Key words: cancer, case–control study, epidemiology, family history, risk factors
introduction
Familial and, hence more likely, genetic factors have a relevant
role in cancer risk and may interact with environmental
exposures. Epidemiologists have used family history (FH),
usually of ﬁrst-degree relatives (FDRs), as a marker for genetic
risk, knowing that FH reﬂects the consequences of genetic
susceptibilities, shared environment, and common behaviors.
In general, subjects with a FDR affected by cancer are at
higher risk than the general population for cancer of the same
site [1]. However, the magnitude of the associations with FH
varies between studies, cancer sites, and strata of sex and age,
being generally stronger for younger probands.
In addition to well-documented familial clustering for most
cancer sites, aggregation of selected types of cancers in families
has also been observed. Findings of systematic analyses of the
aggregation of different cancers have been published, in single
reports, from the Utah [2] and Icelandic [3] population
databases, the nationwide Swedish Family-Cancer Database
[4] and the American Cancer Society Cancer Prevention
Study-1 [5].
The ﬁrst three databases [2–4] are based on unselected
populations and offer important advantages in terms of lack of
selection and recall bias. However, they have no information on
study subjects’ characteristics and lifestyle habits for adjustment
purposes.
Since the early 1990s, this study group carried out a network
of integrated case–control studies on cancer in Italy and
Switzerland. From these data, we can compute relative risks of
cancer at several sites with reference to FH of cancer at any site,
adjusting for major confounding factors.
materials andmethods
This investigation is part of a large network of case–control studies
conducted, between 1991 and 2009, in various areas of northern (the greater
Milan area; the provinces of Pordenone, Padua, Udine, Gorizia, and Forlì;
the urban area of Genoa), central (the provinces of Rome and Latina), and
southern (the urban area of Naples) Italy, and in the Canton of Vaud,
Switzerland. Information was collected, overall, on a total of 1468 cases of
cancer of the oral cavity and pharynx [6], 198 of the nasopharynx [7], 505 of
the esophagus [8], 230 of the stomach [9], 2390 of the colorectum [10], 185
of the liver [11], 326 of the pancreas [12], 852 of the larynx [13], 3034 of the
breast [14], 367 of the endometrium [15], 1031 of the ovary [16], 1294 of the
prostate [17], 767 of the renal cell [18], and a total of 11 557 corresponding
controls (supplementary Table S1, available at Annals of Oncology online).
All studies included incident cases, identiﬁed in the major teaching and
general hospitals of the study areas. Controls were subjects admitted to the
same network of hospitals of cases for a wide spectrum of acute, non-
neoplastic conditions unrelated to known or potential risk factors for the
corresponding cancer site. Overall, 7.5% of controls were admitted for
traumatic conditions, 23.1% for nontraumatic orthopedic conditions, 32.6%
for acute surgical conditions, and 36.8% for miscellaneous other illnesses.
The proportion of refusals of subjects approached was <5% in the Italian
centers, and about 15% in Switzerland. The study protocols were revised and
approved by the local ethics committees of the hospitals involved and all
participants gave informed consent.
Cases and controls were interviewed during their hospital stay using a
structured questionnaire, including information on sociodemographic
characteristics, anthropometric measures, lifestyle habits (e.g. tobacco
smoking and alcohol drinking), dietary habits, personal medical history,
and, for women, menstrual and reproductive factors, use of oral
contraceptives (OCs) and hormone replacement therapy (HRT). Subjects
were speciﬁcally asked for the number of siblings, and whether they, their
parents, children, grandparents or spouses were ever affected by any form of
cancer (excluding nonmelanomatous skin cancer). For each relative with a
history of cancer, the subject was asked to report the vital status at the time
of interview, current age or the age at death, cancer site, and age at diagnosis.
In our analysis, we considered the history of cancer in FDRs only, i.e.
parents, siblings, and sons/daughters. On account of recall and classiﬁcation
difﬁculties, some sites were combined (i.e., all colorectum, Hodgkin and
non-Hodgkin lymphoma, multiple myeloma and leukemia, as well as cervix
and corpus uteri).
statistical analysis
Odds ratios (ORs) of cancer at 13 different sites according to FH of cancers
in FDRs and the corresponding 95% conﬁdence intervals (CIs) were
estimated by unconditional multiple logistic regression models. The models
included terms for quinquennium of age, sex (when appropriate), study
center (when appropriate), year of interview, education, alcohol drinking,
tobacco smoking, body mass index, and number of brothers and sisters. For
female genital tract and breast cancers, models included further terms for
parity, menopausal status, age at menopause, and OC and HRT use, and, for
breast cancer only, age at ﬁrst birth. Additional models were used to assess
the potential modifying effect of sex and age at diagnosis.
To account for the effects of multiple testing, in further analyses the
Benjamini–Hochberg procedure was used to control the false discovery rate
at the desired level of 0.05 [19].
All statistical analyses were carried out with SAS 9.1 statistical software
(SAS Institute, Cary, NC).
results
Table 1 gives the ORs and 95% CIs for 13 cancer sites according
to FH of the concordant cancer, overall and by sex and age of
the proband. The risk of developing cancer at a particular site
increased, although not always signiﬁcantly, in subjects with a
FDR affected by cancer at the same site, with ORs ranging from
1.2 for nasopharyngeal cancer to 7.4 for ovarian cancer.
In general, ORs were consistent according to the sex of the
proband. For most cancer sites, the association with FH was
stronger when the proband was affected at age <60 years. This
was more marked for liver (OR = 10.5 versus 2.1), ovarian
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(OR = 20.1 versus 3.2), and prostate cancers (OR = 5.8 versus
3.3). When the proband was diagnosed before 50 years of age,
the ORs for FH of the concordant cancer were even stronger, in
particular for colorectal (OR = 4.3, 95% CI 2.5–7.6) and breast
(OR = 3.0, 95% CI 1.9–4.5) cancers (data not shown).
Table 2 shows discordant sites with signiﬁcant or borderline
signiﬁcant associations, overall and by sex and age of the
proband. After controlling for multiple testing, the following
discordant site associations were signiﬁcant at α = 0.05: oral and
pharyngeal cancer and FH of laryngeal cancer (OR = 3.3),
esophageal cancer and FH of oral and pharyngeal cancer
(OR = 4.1), breast cancer and FH of colorectal cancer (OR = 1.5)
and of hemolymphopoietic cancers (OR = 1.7), ovarian cancer
and FH of breast cancer (OR = 2.3), and prostate cancer and FH
of bladder cancer (OR = 3.4). For most associations, similar ORs
were estimated for males and females. Some associations were
somewhat stronger when cancer occurred before 60 years of age
in the proband. This is particularly evident for colorectal cancer
and FH of ovarian cancer (OR = 3.0 versus 1.5) and of prostate
cancer (OR = 2.1 versus 1.2), endometrial cancer and FH of
stomach cancer (OR = 2.8 versus 1.2), and ovarian cancer and
FH of hemolymphopoietic cancers (OR = 2.0 versus 0.8).
Positive (though not statistically signiﬁcant) associations were
found for colorectal cancer and FH of endometrial cancer
(OR = 1.7, 95% CI 0.8–3.4) as well as for endometrial cancer
and FH of colorectal cancer (OR = 1.6, 95% CI 0.9–2.9).
Supplementary Table S2, available at Annals of Oncology
online shows ORs of cancer at 13 different sites for FH of the
concordant cancer and FH of cancer at those discordant sites
that revealed signiﬁcant associations after adjustment for
multiple testing by age at cancer diagnosis in the affected
relative. No signiﬁcant heterogeneity was found between ORs
for relatives affected before and those affected after the age of 60
years, with the exception of laryngeal cancer and FH of
laryngeal cancer, breast cancer and FH of breast cancer and of
hemolymphopoietic cancers, endometrial cancer and FH of
uterine cancer, and ovarian cancer and FH of breast cancer, for
which a stronger association emerged for relatives affected at a
younger age.
discussion
In this investigation, we provide a comprehensive picture of the
associations between FH of cancer and cancer risk, using
original data from a large network of case–control studies from
Italy and Switzerland. Our data conﬁrmed and further
quantiﬁed known associations with FH of cancer at concordant
sites for 13 different cancers. Several increased risks for FH of
cancer at discordant sites also emerged, with the following
associations remaining signiﬁcant after controlling for multiple
testing: oral and pharyngeal cancer and FH of laryngeal cancer,
esophageal cancer and FH of oral and pharyngeal cancer, breast
Table 1. Odds ratios (ORs) and 95% conﬁdence intervals (CIs) of cancer at 13 different sites according to family history (FH) of the concordant cancer,
overall and by sex and age of the proband (Italy and Switzerland, 1991–2009)
Cancer Cases with FH (%) Controls with FH (%) ORa (95% CI)
Overallb Sex of the proband Age at cancer onset in the
proband
Male Female <60 years ≥60 years
Oral cavity and pharynx 53 (3.6) 47 (1.2) 2.6 (1.6–4.2) 2.9 (1.6–5.4) 2.2 (1.0–5.1) 3.4 (1.6–7.2) 2.0 (1.1–3.9)
Nasopharynxc 3 (1.5) 6 (1.0) 1.2 (0.3–5.7) 1.5 (0.2–9.2) NEd NEe 3.4 (0.5–23.7)
Esophagus 12 (2.4) 14 (1.1) 1.7 (0.6–4.5) 1.7 (0.6–5.2) 2.2 (0.2–26.9) 0.7 (0.2–3.3) 3.1 (0.7–12.7)
Stomach 30 (13.0) 31 (5.7) 2.7 (1.6–4.6) 2.2 (1.0–4.8) 3.7 (1.6–8.4) 2.5 (1.0–6.2) 2.8 (1.4–5.7)
Colorectum 221 (9.2) 166 (3.4) 2.8 (2.3–3.5) 2.8 (2.1–3.8) 2.8 (2.0–3.9) 3.3 (2.4–4.5) 2.5 (1.9–3.3)
Liver 22 (11.9) 18 (4.5) 3.0 (1.4–6.5) 2.9 (1.1–7.5) 4.2 (0.9–20.5) 10.5 (1.9–59.4) 2.1 (0.9–5.1)
Pancreas 10 (3.1) 15 (2.3) 1.4 (0.5–3.3) 0.9 (0.2–3.4) 2.0 (0.5–7.8) 1.3 (0.3–5.1) 1.7 (0.5–6.1)
Larynx 29 (3.4) 27 (1.4) 2.8 (1.5–5.1) 3.2 (1.7–6.0) NEf 3.5 (1.4–8.7) 2.2 (1.0–5.1)
Breast 311 (10.3) 145 (4.3) 2.6 (2.1–3.2) – 2.6 (2.1–3.2) 2.4 (1.8–3.1) 2.8 (2.0–3.9)
Endometriumg 19 (5.2) 25 (3.1) 2.0 (1.0–4.0) – 2.0 (1.0–4.0) 2.5 (0.9–6.6) 1.4 (0.5–3.6)
Ovary 27 (2.6) 9 (0.4) 7.4 (3.3–16.6) – 7.4 (3.3–16.6) 20.1 (4.5–89.7) 3.2 (1.1–9.4)
Prostate 90 (7.0) 28 (1.9) 3.9 (2.4–6.2) 3.9 (2.4–6.2) – 5.8 (2.3–14.6) 3.3 (1.9–5.7)
Renal cell 18 (2.3) 8 (0.5) 4.2 (1.8–9.8) 3.9 (1.3–11.6) 4.8 (1.2–19.9) 4.1 (1.2–13.7) 4.2 (1.2–14.4)
aAdjusted for age, sex (when appropriate), study center (when appropriate), year of interview, education, body mass index, alcohol drinking, tobacco smoking,
and number of brothers and sisters. Reference category: no family history of the selected cancer. Odds ratios for endometrial and ovarian cancer were further
adjusted for menopausal status, age at menopause, oral contraceptive and hormone replacement therapy use, and parity; odds ratios for breast cancer were
further adjusted for menopausal status, age at menopause, oral contraceptive and hormone replacement therapy use, parity and age at ﬁrst birth.
bIn bold typefaced signiﬁcant associations at level 0.05 after adjustment for multiple testing according to the Benjamini–Hochberg method.
cNasopharyngeal cancer and family history of oral and pharyngeal cancer.
dOnly one female case and two female controls reported a family history of oral and pharyngeal cancer.
eNo cases of nasopharyngeal cancer with age <60 years reported a family history of oral and pharyngeal cancer.
fNo female cases of laryngeal cancer reported a family history of laryngeal cancer.
gEndometrial cancer and family history of uterine cancer (including cervical and endometrial cancer, and cancer at uterus not otherwise speciﬁed).
NE, not estimable.
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cancer and FH of colorectal cancer and of hemolymphopoietic
cancers, ovarian cancer and FH of breast cancer, and prostate
cancer and FH of bladder cancer.
Most of the increased risks found for FH are supported by
existing evidence pointing to genetic aspects of cancer.
Mutation in BRCA1 and BRCA2 genes are associated to breast
and ovarian cancer, and (though less strongly) to other sites like
colon, prostate, and pancreas [20, 21]. For discordant sites,
BRCA1/2mutations presumably contributed to the observed
clustering of breast, ovarian, colorectal and prostate cancers
(an increased, although nonsigniﬁcantly, breast cancer risk was
observed for FH of ovarian cancer, with an OR of 1.7).
Table 2. Signiﬁcant or of borderline signiﬁcance odds ratios (ORs) and 95% conﬁdence intervals (CIs) of cancer at 13 different sites according to family
history (FH) of discordant cancers, overall and by sex and age of the proband (Italy and Switzerland, 1991–2009)
Cancer FH Cases with FH (%) Controls with FH (%) ORa (95% CI)
Overallb Sex of the proband Age at cancer onset in the
proband
Male Female <60 years ≥60 years
OP Larynx 33 (2.2) 25 (0.7) 3.3 (1.7–6.3) 2.9 (1.4–6.2) 4.4 (1.4–14.0) 3.3 (1.4–7.9) 3.6 (1.4–9.3)
Skin 8 (0.5) 7 (0.2) 3.3 (1.0–10.7) 5.1 (0.8–31.4) 2.0 (0.4–11.4) NEc 5.6 (1.4–22.4)
Breast 65 (4.4) 111 (3.0) 1.5 (1.0–2.2) 1.6 (1.0–2.5) 1.4 (0.7–2.6) 1.4 (0.8–2.4) 1.6 (0.9–2.6)
Nasopharynx Colorectum 12 (6.1) 17 (2.9) 3.1 (1.4–7.0) 1.9 (0.7–5.1) 24.4 (3.2–189.1) 4.0 (1.5–11.0) 2.5 (0.5–12.8)
Esophagus OP 21 (4.2) 12 (1.0) 4.1 (1.7–9.8) 5.6 (2.0–16.1) NEd 5.0 (1.2–20.5) 3.6 (1.2–11.0)
Stomach 29 (5.7) 39 (3.1) 1.8 (1.0–3.3) 1.6 (0.8–3.3) 2.9 (0.7–11.9) 2.5 (0.8–7.1) 1.6 (0.7–3.6)
Colorectum Stomach 132 (5.5) 224 (4.5) 1.2 (1.0–1.6) 1.2 (0.9–1.7) 1.1 (0.8–1.6) 1.3 (0.9–1.8) 1.2 (0.9–1.6)
Liver 91 (3.8) 141 (2.9) 1.4 (1.0–1.8) 1.1 (0.8–1.7) 1.8 (1.2–2.7) 1.5 (0.9–2.4) 1.3 (0.9–1.9)
Ovary 15 (0.6) 17 (0.3) 2.1 (1.0–4.2) 2.6 (0.7–9.8) 2.0 (0.8–5.1) 3.0 (1.1–8.5) 1.5 (0.6–4.0)
Prostate 39 (1.6) 55 (1.1) 1.6 (1.0–2.4) 1.5 (0.8–2.7) 1.4 (0.7–2.6) 2.1 (1.2–3.8) 1.2 (0.6–2.1)
HLPC 52 (2.2) 82 (1.7) 1.4 (1.0–2.0) 1.4 (0.9–2.3) 1.4 (0.8–2.4) 1.3 (0.7–2.2) 1.4 (0.9–2.3)
Pancreas Stomach 21 (6.4) 20 (3.1) 2.4 (1.2–4.7) 3.6 (1.2–10.3) 1.9 (0.7–5.0) 3.0 (0.7–11.9) 2.0 (0.9–4.5)
Larynx Colorectum 49 (5.8) 80 (4.1) 1.5 (1.0–2.3) 1.4 (0.9–2.3) 3.5 (0.7–17.4) 1.3 (0.6–3.0) 1.6 (0.9–2.7)
Skin 7 (0.8) 3 (0.2) 8.4 (1.7–41.8) 14.4 (1.7–125.0) NEe 6.1 (1.1–33.8) NEf
Breast Stomach 148 (4.9) 138 (4.1) 1.2 (1.0–1.6) – 1.2 (1.0–1.6) 1.3 (0.9–1.8) 1.2 (0.8–1.7)
Colorectum 150 (4.9) 112 (3.3) 1.5 (1.1–1.9) – 1.5 (1.1–1.9) 1.8 (1.3–2.6) 1.2 (0.8–1.7)
Skin 26 (0.9) 10 (0.3) 3.0 (1.4–6.4) – 3.0 (1.4–6.4) 1.9 (0.8–4.5) 6.2 (1.3–28.8)
Uterus 108 (3.6) 84 (2.5) 1.4 (1.0–1.9) – 1.4 (1.0–1.9) 1.5 (1.0–2.2) 1.2 (0.8–2.0)
Prostate 59 (1.9) 42 (1.2) 1.6 (1.1–2.4) – 1.6 (1.1–2.4) 1.3 (0.8–2.2) 2.1 (1.1–4.3)
HLPC 92 (3.0) 57 (1.7) 1.7 (1.2–2.4) – 1.7 (1.2–2.4) 2.0 (1.2–3.1) 1.4 (0.9–2.4)
Endometrium Stomach 22 (6.0) 32 (4.0) 1.8 (1.0–3.4) – 1.8 (1.0–3.4) 2.8 (1.1–7.2) 1.2 (0.5–2.7)
Kidney 6 (1.6) 5 (0.6) 4.2 (1.0–16.5) – 4.2 (1.0–16.5) 1.7 (0.3–11.0) 7.3 (1.1–50.3)
Brain 10 (2.7) 7 (0.9) 4.2 (1.3–13.3) – 4.2 (1.3–13.3) 3.5 (0.5–22.9) 3.4 (0.8–14.9)
Ovary Colorectum 60 (5.8) 89 (3.7) 1.6 (1.1–2.4) – 1.6 (1.1–2.4) 1.7 (1.1–2.7) 1.6 (0.8–2.9)
Larynx 24 (2.3) 42 (1.7) 1.8 (1.0–3.2) – 1.8 (1.0–3.2) 1.7 (0.9–3.4) 1.9 (0.6–5.7)
Breast 104 (10.1) 111 (4.6) 2.3 (1.7–3.2) – 2.3 (1.7–3.2) 1.9 (1.3–2.9) 2.8 (1.8–4.4)
HLPC 32 (3.1) 54 (2.2) 1.6 (1.0–2.5) – 1.6 (1.0–2.5) 2.0 (1.1–3.5) 0.8 (0.3–2.0)
Prostate Colorectum 84 (6.5) 58 (4.0) 1.5 (1.0–2.2) 1.5 (1.0–2.2) – 1.3 (0.6–2.8) 1.6 (1.0–2.5)
Lung 111 (8.6) 88 (6.1) 1.5 (1.1–2.0) 1.5 (1.1–2.0) – 1.4 (0.7–2.7) 1.5 (1.0–2.2)
Ovary 10 (0.8) 2 (0.1) 7.4 (1.4–38.2) 7.4 (1.4–38.2) – 0.9 (0.1–17.2) NEg
Bladder 31 (2.4) 10 (0.7) 3.4 (1.6–7.3) 3.4 (1.6–7.3) – 4.0 (1.1–15.4) 3.2 (1.3–8.2)
Kidney 16 (1.2) 6 (0.4) 3.4 (1.2–9.4) 3.4 (1.2–9.4) – 2.7 (0.5–14.3) 3.9 (1.0–14.9)
Renal cell Uterus 26 (3.4) 32 (2.1) 1.7 (1.0–3.0) 2.3 (1.1–4.7) 1.2 (0.5–2.8) 0.9 (0.3–3.3) 1.6 (0.9–3.0)
aAdjusted for age, sex (when appropriate), study center (when appropriate), year of interview, education, body mass index, alcohol drinking, tobacco smoking,
and number of brothers and sisters. Reference category: no family history of the selected discordant cancer. Odds ratios for endometrial and ovarian cancers
were further adjusted for menopausal status, age at menopause, oral contraceptive and hormone replacement therapy use, and parity; odds ratios for breast
cancer were further adjusted for menopausal status, age at menopause, oral contraceptive and hormone replacement therapy use, parity and age at ﬁrst birth.
bIn bold typefaced, in the overall analysis, signiﬁcant associations at level 0.05 after adjustment for multiple testing according to the Benjamini–Hochberg
method.
cOnly one case and three controls with age <60 years reported a family history of skin cancer.
dOnly one female case and ﬁve female controls reported a family history of oral and pharyngeal cancer.
eNo female case reported a family history of skin cancer.
fOnly two cases and no control with age ≥60 years reported a family history of skin cancer.
gNine cases and no control with age ≥60 years reported a family history of ovarian cancer.
HLPC, hemolymphopoietic cancers; NE, not estimable; OP, oral cavity and pharynx.
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Mutations in mismatch repair genes involved in the Lynch
syndrome (i.e.,MSH2 andMLH1) increase the risk of colorectal
and endometrial adenocarcinomas, and, to a smaller extent,
ovarian cancer [22]. These mutations could therefore be
responsible for part of the identiﬁed associations between
colorectal and endometrial cancers and FH of cancer at
concordant sites, as well as of the cluster of colorectal and
ovarian cancers. We found a signiﬁcant association between
breast cancer and FH of hemolymphopoietic cancers, with an
OR of 1.5 (95% CI 1.0–2.7) for FH of leukemia. Breast cancer
and leukemia have been linked within families that have rare
germline mutations in either the p53 gene (Li-Fraumeni
Syndrome) or ataxia telangiectasia gene [23].
Although most of these cancer susceptibility genes confer a
high risk of developing the disease and are highly penetrant,
they are too rare to account for a substantial proportion of
common cancers; there may also be predisposing genes of lower
penetrance that account for a larger proportion of cancers [1].
This is the case of common polymorphisms in genes involved in
the metabolism of exogenous or endogenous mutagens or in the
production of sex hormones or their analogues [24].
Further, environmental exposures and habits shared by
family members may account for some of the observed familial
clustering of cancers. In particular, alcohol and tobacco, alone
or in combination, are associated with an increased risk of
various cancers [25], with increased relative risks up to 100-fold
for oral and pharyngeal cancer in the highest consumption level
[26]. Moreover, shared dietary factors may play a role in some of
the observed associations, in particular among digestive tract
cancers. H. pylori infection, which tends to aggregate among
family members [27], may contribute to the associations
between FH of stomach cancer and the risk of stomach cancer
and pancreatic cancer, whose risk is increased among H. pylori-
infected subjects [28]. Another possible shared factor explaining
the associations between kidney and uterine/endometrial
cancers, in both directions, and breast cancer and FH of
colorectal cancer is obesity, which increases the risk of these
cancers [29] and runs in families. For the breast–FH of prostate
cancer association, potentially shared hormonal mechanisms
have recently been suggested [30].
Some of the discordant site associations that emerged in our
analyses, such as those between oral and pharyngeal cancer and
FH of skin cancer, or nasopharyngeal cancer and FH of
colorectal cancer, have not been consistently reported in the
literature and may be chance ﬁndings; any inference remains
therefore speculative. Some others are based on a limited
number of exposed cases and controls and need independent
conﬁrmation. On the other hand, we cannot exclude that some
existing associations did not emerge in our analysis due to
insufﬁcient statistical power, particularly when the strength of
the relation is modest, or the cancer(s) is rare.
Some of our ﬁndings on cross site associations have been
previously reported from studies conducted on population-
based databases [2–4]. These include clusters of prostate, kidney
and bladder cancers [2–4], prostate and colorectal cancers [2, 3],
ovarian and breast cancers [3, 4], breast and prostate cancers
[3, 4], and colorectal and prostate cancers [2, 3]. Moreover,
consistently with our ﬁndings, the Swedish database showed an
association between colorectal and breast cancers [4].
In our case–control studies, selection bias should be limited
as we included in the control group subjects admitted to
hospital for a wide spectrum of acute, non-neoplastic
conditions, unrelated to the major risk factors for cancer.
Moreover, the almost complete participation has likely reduced
selection bias. The male/female ratio was high for several cancer
sites, and particularly for oral cavity and pharynx, nasopharynx,
esophagus, liver, and larynx. This reﬂects actual differences
observed in Italy in the incidence of these cancers between the
two sexes. This is not surprising in our population, where
(combined) alcohol and tobacco consumption was considerably
more common in men than women in the past.
Data on FH of cancer was self-reported, and it is possible that
cancer patients may be more interested in understanding their
family cancer history in greater detail, especially if multiple
family members have been affected by a speciﬁc cancer.
However, the similar hospital setting of the interview should
have improved the comparability of the information collected.
An analysis in our population showed a satisfactory reliability of
data on FH of all cancers provided by hospital controls, with a
kappa statistic of 0.70 for all cancers, 0.70 for liver cancer, and
0.80 for any digestive tract cancers [31]. In a recent systematic
review from the US Agency for Healthcare Research and
Quality, self-reported FH of common cancers appeared to be
fairly accurate: speciﬁcity across all cancer types ranged from
91% to 99%, while sensitivity values showed greater variability,
with breast cancer having the highest values (around 85%–90%)
[32]. In the Connecticut Family Health Study, reports from
FDRs were more accurate than those from second degree
relatives; we therefore considered FDRs only in our analysis
[33]. With reference to confounding, we were able to adjust for
the main recognized risk factors, including tobacco smoking,
alcohol drinking, overweight/obesity, and, for female genital
tract and breast cancers, reproductive factors.
In the analysis of the association between 13 different cancer
sites and FH of cancer at 18 sites, the total number of available
comparisons is 234, and the problem of multiple comparisons is
an important issue. Several adjustment techniques have been
proposed recently [19], and we checked for consistency of
results obtained according to traditional and newly developed
methods. However, in conformity with the exploratory aim of
this study and with the existing literature, we commented both
adjusted and unadjusted results for multiple comparisons,
though more relevance should be given to associations that were
still signiﬁcant after adjustment for multiple testing.
In conclusion, our results point to several potential cancer
syndromes that appear among close relatives and may
indicate the presence of genetic factors inﬂuencing multiple
cancer sites.
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